Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.

Fiche publication

Date publication

mai 2017

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AVEROUS Gerlinde , Mr MONNIEN Franck , Pr BIBEAU Frédéric

Tous les auteurs :
Valmary-Degano S, Colpart P, Villeneuve L, Monnien F, M'Hamdi L, Lang Averous G, Capovilla M, Bibeau F, Laverriere MH, Verriele-Beurrier V, Ben Rejeb H, Dartigues P, Hommell-Fontaine J, Gilly FN, Isaac S, Mery E,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28619621

Résumé

Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM.